- Home
- Products
LYNPARZA (Olaparib)
LYNPARZA (Olaparib)
- Medicine Name: Lynparza
- Generic Name: Olaparib
- Dosage Form & Strength: Tablets – 100 mg and 150 mg
- Manufactured By: AstraZeneca
- FDA Approval Date: December 19, 2014
Lynparza is a PARP inhibitor used for treating various cancers with BRCA mutations or homologous recombination repair (HRR) gene alterations.
Indications include:
Ovarian Cancer
- Maintenance therapy for BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer after platinum-based chemotherapy
- Combination with Bevacizumab for HRD-positive ovarian cancer
- Treatment of recurrent BRCA-mutated ovarian cancers
Breast Cancer
- HER2-negative, high-risk early breast cancer with gBRCA mutation
- HER2-negative metastatic breast cancer with gBRCA mutation (with prior chemotherapy)
Pancreatic Cancer
- Maintenance treatment for gBRCAm metastatic pancreatic adenocarcinoma post platinum-based chemotherapy
Prostate Cancer
- mCRPC with germline or somatic HRR gene mutations after progression on enzalutamide or abiraterone
- In combination with abiraterone and prednisone or prednisolone for BRCA-mutated mCRPC
Recommended Dosage:
300 mg (two 150 mg tablets) orally twice daily with or without food. Dose adjustment may be needed for renal impairment. Tablets should be swallowed whole.
Risk of MDS/AML: Monitor blood counts regularly. Discontinue if confirmed.
Risk of pneumonitis: Discontinue permanently if diagnosed.
Venous thromboembolism risk: Monitor for signs of DVT or PE.
Fetal toxicity: Avoid use during pregnancy. Use contraception and discontinue breastfeeding during and for 1 month after therapy.
Documents Required for Import:
- Valid prescription from a qualified doctor
- Diagnostic reports
- Government-issued patient ID
- Import permit, if applicable
Availability in India:
Lynparza is not commercially available in Indian pharmacies. It can be imported under the Named Patient Program to cities including Mumbai, Delhi, Bangalore, Chennai, Hyderabad, Ahmedabad, and others.
Global Rare Meds sources Lynparza from certified suppliers in the USA, Canada, Europe, and Australia.
- Fulfilled and verified by registered pharmacists
- Dispatched from our Ambernath, Thane District fulfillment center
- Shipped with regulatory compliance and global delivery
What is the generic name of Lynparza?
Olaparib
Who manufactures Lynparza?
Jointly developed and marketed by AstraZeneca and MSD
What cancers does Lynparza treat?
Ovarian, breast, pancreatic, and prostate cancers with BRCA or HRR mutations
What dosage forms are available?
Tablets – 100 mg and 150 mg
What is the standard dosage?
300 mg twice daily (2 x 150 mg tablets). Dose may vary based on renal function.
Is Lynparza FDA approved?
Yes, approved on December 19, 2014
What are the common side effects?
- As monotherapy: nausea, fatigue, anemia, vomiting, decreased appetite
- With bevacizumab: anemia, lymphopenia, UTI, diarrhea
- With abiraterone: anemia, dizziness, abdominal pain, diarrhea
Is Lynparza available in India?
Yes, via Named Patient Import Authorization
How much does Lynparza cost in India?
Contact Global Rare Meds for the latest pricing:
Phone: +91-99675 15602
WhatsApp: +91-99675 15602
Email: info@globalraremeds.com
How should Lynparza be stored?
Store at 20°C to 25°C. Excursions permitted between 15°C and 30°C. Protect from moisture.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
